Literature DB >> 8793383

Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation.

Q He1, S Skog, N Wang, S Eriksson, B Tribukait.   

Abstract

An affinity-purified anti-TK1 antibody (pAb1) raised against a synthetic peptide (amino acids K211PGEAVAARKLFAPQ225) corresponding to part of the C-terminus of human cytosolic thymidine kinase (TK1) was produced and characterized by enzyme-linked immunosorbent assay, Western immunoblotting and immunoprecipitation as well as by immunostaining of intact cells. pAb1 recognized a single 25 kDa TK1 polypeptide in extracts of human and rodent cells. The protein was localized to the cytoplasm, as studied by immunohistochemistry and there was no staining in G1/G0 cells or mutant cells lacking TK1 activity, while it was high in S-phase and G2 cells. When series of peptides were tested for antibody binding in which alanine was replacing each of the other amino acids one by one, lysines 211 and 220, proline 212 and glutamic acid 214 were found to be important for antibody reactivity. These results indicate that amino acids 211-214, which may form a turn region, constitute a major recognition site for pAb1, and this structure may also be involved in the cell cycle-dependent modification of TK1, pAb1 is a very useful tool for studies of the cell cycle regulation of TK1, and it may be used to identify and quantify rapidly proliferating cells such as tumor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8793383

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  12 in total

1.  Human deoxycytidine kinase is located in the cell nucleus.

Authors:  M Johansson; S Brismar; A Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings.

Authors:  Yan Chen; Mingang Ying; YanSong Chen; Minhua Hu; Yingying Lin; Dedong Chen; Xiaoli Li; Ming Zhang; Xia Yun; Ji Zhou; Ellen He; Sven Skog
Journal:  Int J Clin Oncol       Date:  2010-04-01       Impact factor: 3.402

3.  Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2'-deoxy-2'-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity.

Authors:  J Wang; S Eriksson
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients.

Authors:  Zhu-Lin Pan; Xing-Ying Ji; Yan-Min Shi; Ji Zhou; Ellen He; Sven Skog
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-07       Impact factor: 4.553

5.  X-irradiation effects on thymidine kinase (TK): I. TK1 and 2 in normal and malignant cells.

Authors:  Q He; S Skog; I Welander; B Tribukait
Journal:  Cell Prolif       Date:  2002-04       Impact factor: 6.831

6.  Serum thymidine kinase 1 concentration in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors.

Authors:  Wei Xu; Xin Cao; Kou-Rong Miao; Chun Qiao; Yu-Jie Wu; Qiong Liu; Lei Fan; Jian-Yong Li
Journal:  Int J Hematol       Date:  2009-07-24       Impact factor: 2.490

7.  Differential intracellular compartmentalization of herpetic thymidine kinases (TKs) in TK gene-transfected tumor cells: molecular characterization of the nuclear localization signal of herpes simplex virus type 1 TK.

Authors:  B Degrève; M Johansson; E De Clercq; A Karlsson; J Balzarini
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

8.  Nuclear TK1 expression is an independent prognostic factor for survival in pre-malignant and malignant lesions of the cervix.

Authors:  Gang Chen; Cheng He; Ling Li; An Lin; Xiongwei Zheng; Ellen He; Sven Skog
Journal:  BMC Cancer       Date:  2013-05-21       Impact factor: 4.430

9.  A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.

Authors:  J Kiran Kumar; A C Aronsson; G Pilko; M Zupan; K Kumer; T Fabjan; J Osredkar; S Eriksson
Journal:  Tumour Biol       Date:  2016-04-14

Review 10.  Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases.

Authors:  An R Van Rompay; Magnus Johansson; Anna Karlsson
Journal:  Pharmacol Ther       Date:  2003-11       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.